Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Daiichi Life Offers $4.4 Billion to Buy Rest of Challenger

Daiichi Life Group Inc. offered to buy the remainder of Challenger Ltd. that it doesn’t already own, in a takeover bid that valued the Australian firm at around A$7.9 billion ($5.5 billion).

We haven't written up this one. Bloomberg has the full story — the link below goes straight to it.

Read the original at bloomberg.com →

More in Finance & Markets

Where Will CRISPR Therapeutics Stock Be in 2030?

The company's expertise in gene editing could lead to more breakthroughs.

  • CRISPR Therapeutics stock declined 47% since mid-2021 while S&P 500 gained 73%.
  • Received approval for Casgevy, first CRISPR-based gene-editing therapy in 2023.
  • Promising pipeline candidates include LDL cholesterol reducer CTX310 and anticoagulant CTX611.

More from Sunday 18 October →